It has been reported to be a tumour-associated antigen present in both melanocytes and melanoma and as such, TRP-2 has been intensely studied as a viable therapeutic and prophylactic vaccine candidate for melanoma and glioblastoma [18, 19]. The gene discussed is DCT; the disease is glioblastoma.